Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism

Area of Science:

• Cardiology
• Pharmacology
• Metabolic Disorders

Background:

• Low high-density lipoprotein (HDL) cholesterol is a significant predictor of coronary artery disease (CAD) risk.
• Current dyslipidemia guidelines have updated the definition of low HDL cholesterol from <35 mg/dL to <40 mg/dL.
• Understanding pharmacological interventions to increase HDL cholesterol is crucial for cardiovascular risk management.

Purpose of the Study:

• To review current pharmacological agents that increase high-density lipoprotein (HDL) cholesterol.
• To discuss the efficacy and additive effects of various drug classes on HDL cholesterol levels.
• To highlight the importance of HDL cholesterol in cardiovascular disease risk.

Main Methods:

• Literature review of pharmacological agents affecting HDL cholesterol.
• Analysis of drug classes including statins, fibrates, niacin, thiazolidinediones, estrogen, and omega-3 fatty acids.
• Examination of additive effects and mechanisms of action.

Main Results:

• Statins and fibrates moderately increase HDL cholesterol, with additive effects when used together.
• Niacin is a potent HDL-raising agent, also showing additive effects with statins.
• Other agents like thiazolidinediones, estrogen, and omega-3 fatty acids also increase HDL cholesterol through various mechanisms.

Conclusions:

• Multiple pharmacologic classes effectively increase HDL cholesterol, offering therapeutic options for dyslipidemia.
• The mechanisms underlying HDL-raising effects of non-statin agents require further elucidation.
• Targeting HDL cholesterol remains an important consideration in managing cardiovascular disease risk.